TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02714296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nutridrink 200 ml
Description: Nutridrink 200 ml 6 bottles per day as a sole source of nutrition. On the day of the colonoscopy, as breakfast, allowed Nutridrink 1-2 bottles

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutridrink compact protein
Description: 2 bottles per day. On the day of the colonoscopy, as breakfast, allowed Nutridrink compact protein 1-2 bottles
Study: NCT04226586

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Essential Amino Acid (EAA) group
Description: Eligible children will be supplemented with Essential Amino Acids (EAA) for 6 months twice a day. Caution will be exercised to match the groups for age and sex.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible children will be supplemented with a placebo for 6 months twice a day. Caution will be exercised to match the groups for age and sex.
Study: NCT00131482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chrysalin
Description: Patients were treated with a single percutaneous injection of Chrysalin 3 micrograms at the fracture site at the time of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chrysalin
Description: Patients were treated with a single percutaneous administration of Chrysalin 1 microgram at the fracture site at the time of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chrysalin
Description: Patients were treated with a single percutaneous administration of Chrysalin 10 micrograms at the fracture site at the time of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chrysalin
Description: Patients were treated with a single percutaneous administration of Chrysalin 30 micrograms at the fracture site at the time of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were treated with a single percutaneous administration of placebo at the fracture site at the time of surgery.
Study: NCT01978691

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium animalis ssp. lactis 420
Description: Studied as a probiotic bacteria

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium animalis ssp. lactis 420
Description: Studied as a probiotic bacteria

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polydextrose
Description: Studied as a prebiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polydextrose
Description: Studied as a prebiotic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control
Study: NCT01583634

Intervention type: DEVICE
Intervention: Mespere Oximeter
Description: Mespere oximeter provides non-invasive venous blood oxygen saturation.

Intervention type: DEVICE
Intervention: Radiometer OSM-3 Co-Oximeter
Description: OSM-3, a Radiometer manufactured hemoximeter, is intended for the photometric determination of hemoglobin.
Study: NCT04598633

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289)
Description: Supplementary intake of Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289) 2 times per day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-lozenges (BioGaia)
Description: Placebo-lozenges (BioGaia) 2 times per day for 12 weeks
Study: NCT03990233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765063
Description: mAb antagonist to SIRPα receptor, a myeloid checkpoint inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765063
Description: mAb antagonist to SIRPα receptor, a myeloid checkpoint inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765063
Description: mAb antagonist to SIRPα receptor, a myeloid checkpoint inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765063
Description: mAb antagonist to SIRPα receptor, a myeloid checkpoint inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: mAb antagonist to PD-1 receptor, a lymphocyte T checkpoint inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: mAb antagonist to PD-1 receptor, a lymphocyte T checkpoint inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: mAb antagonist to PD-1 receptor, a lymphocyte T checkpoint inhibitor
Study: NCT01831986

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pregnenolone and L-Theanine
Description: Pregnenolone (50 mg/day) with L-theanine (400 mg/day)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Caps
Study: NCT00501332

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Maxy-G34
Description: Maxy-G34 will be administered by subcutaneous injection during each of 6 TAC chemotherapy cycles.
Study: NCT02704481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo mifepristone
Description: Matching placebo pill of 200mg mifepristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo misoprostol
Description: Matching placebo pills of 800mcg misoprostol
Study: NCT02330965

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood draws (65 mLs \[\~4 tablespoons\] per blood draw) at 4 time points: Prior to study medication initiation, and at +6, +12 and+24 months post treatment initiation.

Intervention type: PROCEDURE
Intervention: CSF collection by lumbar puncture (Optional)
Description: For participants who volunteer to donate CSF samples: up to 25 mLs (\<2 tablespoons): prior to study medication initiation, and at month 24 post treatment initiation.

Intervention type: PROCEDURE
Intervention: CSF collection by lumbar puncture (Optional)
Description: For participants who volunteer to donate CSF samples: up to 25 mLs (\<2 tablespoons): prior to study medication initiation, and at month 24 post treatment initiation.
Study: NCT03890952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Treatment with the combination of Nivolumab and bevacizumab every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Treatment with the combination of Nivolumab and bevacizumab every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Treatment with the combination of Nivolumab and bevacizumab every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Treatment with the combination of Nivolumab and bevacizumab every 2 weeks
Study: NCT01729871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: uninterrupted vitamin K antagonist (VKA)
Description: dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0
Study: NCT01838551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoketoconazole
Description: Levoketoconazole is the 2S,4R- enantiomer derived from racemic ketoconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoketoconazole
Description: Levoketoconazole is the 2S,4R- enantiomer derived from racemic ketoconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoketoconazole
Description: Levoketoconazole is the 2S,4R- enantiomer derived from racemic ketoconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoketoconazole
Description: Levoketoconazole is the 2S,4R- enantiomer derived from racemic ketoconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoketoconazole
Description: Levoketoconazole is the 2S,4R- enantiomer derived from racemic ketoconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoketoconazole
Description: Levoketoconazole is the 2S,4R- enantiomer derived from racemic ketoconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoketoconazole
Description: Levoketoconazole is the 2S,4R- enantiomer derived from racemic ketoconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoketoconazole
Description: Levoketoconazole is the 2S,4R- enantiomer derived from racemic ketoconazole
Study: NCT00508690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefmetazole
Description: Intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: kanamycin/metronidazole
Description: 2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
Study: NCT02064751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT with MultiPoint Pacing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodynamic measurements for CRT device programming
Study: NCT03530280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin (lyrica)
Description: preoperative pregabalin and the postoperative sham block will perform.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: The preoperative placebo oral tablet and the postoperative sham block will perform.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal block including bupivacaine
Description: The preoperative placebo oral tablet and adductor channel block including 10 mL of 0.25% bupivacaine with 5 μg/mL epinephrine
Study: NCT01585181

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PXVX0200
Description: Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Approx 2 grams of lactose reconstituted in water
Study: NCT02093923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX-2930
Description: Participants will receive SC injection of DX-2930 (a recombinant, Chinese hamster ovary \[CHO\] cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody) once and followed by the second dose after 2 week into the upper arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX-2930
Description: Participants will receive SC injection of DX-2930 (a recombinant, Chinese hamster ovary \[CHO\] cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody) once and followed by the second dose after 2 week into the upper arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX-2930
Description: Participants will receive SC injection of DX-2930 (a recombinant, Chinese hamster ovary \[CHO\] cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody) once and followed by the second dose after 2 week into the upper arm.
Study: NCT02770664

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC28-0126 Dose A
Description: LC28-0126 Dose A
Study: NCT02093923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX-2930
Description: Participants will receive SC injection of DX-2930 (a recombinant, Chinese hamster ovary \[CHO\] cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody) once and followed by the second dose after 2 week into the upper arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo subcutaneously.
Study: NCT05908617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Discharge
Description: Patient will watch a video discharge instructions in addition to the standard paper instructions. They will also take the pre and post test as the control group
Study: NCT05352438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy Group
Description: Patient education directed at parafunctional behaviors was given, and an exercise program was taught, with all the patients instructed to perform these exercises at home. The home exercise program included diaphragmatic breathing exercises, chin-tuck exercises, mandibular resistance exercises, and neck muscle stretching exercises. The patients were instructed to perform the exercises as 3 sets of 10 repetitions per day.~In addition to the patient education and home exercises, the Manual Therapy group received a manual therapy program applied as 2 sessions of 45 mins each week for 4 weeks (total 8 sessions) by an investigator. Soft tissue and joint mobilizations were applied to the TMJ and surrounding structures and to cervical segments, trigger point treatment was applied to trigger points, and myofascial loosening was performed. Patients were instructed to perform the exercises learned in the home exercise program in 3 sets of 10 repetitions every day.
Study: NCT02770664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC28-0126 Dose B
Description: LC28-0126 Dose B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC28-0126 Dose C
Description: LC28-0126 Dose C
Study: NCT05352438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Splint Therapy Group
Description: Patient education directed at parafunctional behaviors was given, and an exercise program was taught, with all the patients instructed to perform these exercises at home. The home exercise program included diaphragmatic breathing exercises, chin-tuck exercises, mandibular resistance exercises, and neck muscle stretching exercises. The patients were instructed to perform the exercises as 3 sets of 10 repetitions per day.~In addition to the patient education and home exercises, the Splint Therapy group was given a static occlusal splint, and adjustments were made as necessary. All the patients in this group were instructed to use the splint when sleeping for a period of one month.
Study: NCT04245293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ainara
Description: Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HyaloGin
Description: Active Comparator: HyaloGin Each administration kit (subject kit) for patients allocated to HyaloGyn® group will contain a box with: 1 tube with 30g gel and 10 single-use applicators consisting of a piston and one opaque plastic plunger.~The gel quantity is enough for one subject (3g application every three days over the course of the study).
Study: NCT03084458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: The Fitbit device will allow experimental group participant access to their daily step count.
Study: NCT04459832

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stretch hamstring
Description: Stretching of the hamstring muscles was performed by the primary researcher. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stretch hamstring
Description: Stretching of the hamstring muscles was performed by the primary researcher. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stretch hamstring
Description: Stretching of the hamstring muscles was performed by the primary researcher. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible
Study: NCT00526435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk with Ease - Group
Description: Participate in 6-week, 1 hour per week group assisted classes (with instructor).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk with Ease - Self
Description: SUbject will receive the WWE workbook and follow it without group/instructor assistance.
Study: NCT04459832

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: stretch hamstring
Description: Stretching of the hamstring muscles was performed by the primary researcher. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible
Study: NCT03357822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon
Description: 180ug Pegylated interferon is injected subcutaneously once a week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: 0.5mg entecavir is orally taken every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: 0.5mg entecavir is orally taken every day
Study: NCT00379509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Patients will be assigned in cohorts of 3. Dose levels of GW572106 will include 500mg, 1000mg,1500 mg (additional levels at 750 mg and 1250 mg will be added if needed). Lapatinib is an oral drug. It is taken every day.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: TdT-mediated dUTP nick end labeling assay
Description: Genetic analysis of tumor tissue

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Genetic analysis of tumor tissue.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Genetic analysis of tumor tissue.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Laboratory analysis of tumor tissue.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Serial biopsies by skin punch or core biopsy or fine needle aspiration.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiotherapy will be delivered at standard dose and fractionation. For patients who have not received previous locoregional radiotherapy, 50-56 Gy will be delivered to the regional lymph nodes and/or chest wall at a dose of 2 Gy per fraction, 5 days per week followed by a boost to the sites of gross involvement to a total dose of 60-70 Gy over a course of 6-7 weeks. For patients who have received adjuvant radiotherapy, a dose of 35-45 Gy will be delivered to sites of chest wall involvement at a dose of 1.8 Gy per fraction over 4-5 weeks. In either de novo or reirradiated settings, the total dose to the brachial plexus will not exceed 60 Gy.
Study: NCT01396694

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire
Study: NCT03895229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG Oral Tablet [Jardiance]
Description: Empagliflozin is a sodium-glucose co-transporter 2 inhibitor approved for treatment of type 2 diabetes mellitus
Study: NCT01557062

Intervention type: OTHER
Group type: OTHER
Intervention: Polysomnography
Description: The Embla® S7000 was used to record full-night at the Sleep Institute (São Paulo, Brazil). The sensors were attached to the patient in a non-invasive manner using tape or rubber bands. The physiological variables were monitored simultaneously and continuously: 4 channels of EEG, 2 of EOG, 4 of EMG and 1 channel of ECG. Airflow detection was made through 2 channels using a pair of thermal sensors and nasal pressure. Respiratory effort of the chest and abdomen, were measured by respiratory inductance plethysmography. Oxygen saturation, were measured with a pulse oximeter. Sleep stages were visually scored in all the PSG according to standardized criteria for the investigation of sleep macrostructure.

Intervention type: OTHER
Group type: OTHER
Intervention: Teperature measure
Description: Core body temperature was assessed using a thermistor pill (sensor), which is an electronic device 2.23 cm in length and 1.06 cm in diameter that records body temperature and transmits it to a receptor located at the patient's waist called the Core Body Temperature Monitoring System (CorTempTM), that is powered by a silver oxide battery. The components of the sensor are encapsulated in epoxy resin and coated with silicone (HQ Inc., Florida, USA). To ensure that the sensor would be in the intestines and not the stomach, the pill was ingested at least 2 hours (h) before beginning temperature recording. The CBT was recorded every 30 minutes (min) between 10:00pm and 7:00am. The time of pill elimination is variable between individuals and may be as long as 48h.

Intervention type: OTHER
Group type: OTHER
Intervention: Fibromyalgia Impact questionary
Description: The FIQ is an instrument used to assess the quality of life specifically for patients with FM. This questionnaire consists of 19 questions related to functional capacity, employment status, general well being, psychological disorders and physical symptoms. The higher the score is, the greater is the impact of FM in the individual's quality of life. This questionnaire was validated for Brazilian's population in 2006.
Study: NCT03201263

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigh
Description: Application of cyclic pressure control breath delivered at 30 cmH2O for 3 seconds once per minute in patients undergoing pressure support ventilation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study: NCT04396444

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Aromastick
Description: Vascular surgery patients will be randomized to either the intervention group and receive a lavender infused aromastick to use as an adjunct to their inpatient pain management plan, or to the control group, given a blank aromastick. Subjects will be blinded to their group.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aromastick
Description: Vascular surgery patients will be randomized to either the intervention group and receive a lavender infused aromastick to use as an adjunct to their inpatient pain management plan, or to the control group, given a blank aromastick. Subjects will be blinded to their group.
Study: NCT01015417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin clavulanic acid
Description: Postoperative administration of 2g, 3 times daily, since 5 days, of amoxicillin clavulanic acid (Augmentin or generic) oral form or parenteral form according to clinical patient and by the choice of medical teams